Pacira BioSciences Inc
For the period ended Mar 31, 2025. Filed May 8, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2025 · Filed May 8, 2025
PCRX$36.46+0.1%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 6. Exhibits
The exhibits listed below are filed or furnished as part of this report.
| Exhibit Number | Description |
| 3.1 | Third Amended and Restated Bylaws. (1) |
| 10.1 | Settlement Agreement, dated April 7, 2025, by and between Pacira BioSciences, Inc. and Pacira Pharmaceuticals, Inc. with Fresenius Kabi USA, LLC, eVenus Pharmaceutical Laboratories Inc., and Jiangsu Hengrui Pharmaceuticals Co., Ltd. (f/k/a Jiangsu Hengrui Medicine Co., Ltd.).* †† ## |
| 10.2 | Amended and Restated 2014 Inducement Plan. *** (2) |
| 10.3 | Form of Nonstatutory Stock Option Agreement under the Amended and Restated 2014 Inducement Plan. *** (3) |
| 10.4 | Form of Restricted Stock Unit Award Agreement under the Amended and Restated 2014 Inducement Plan. *** (4) |
| 31.1 | Certification of Chief Executive Officer pursuant to Rule 13a-14(a) and 15d-14(a), as amended.* |
| 31.2 | Certification of Chief Financial Officer pursuant to Rule 13a-14(a) and 15d-14(a), as amended.* |
| 32.1 | Certification of Chief Executive Officer and Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.** |
| 101 | The following materials from the Quarterly Report on Form 10-Q of Pacira BioSciences, Inc. for the quarter ended March 31, 2025, formatted in iXBRL (Inline eXtensible Business Reporting Language): (i) the Condensed Consolidated Balance Sheets; (ii) the Condensed Consolidated Statements of Operations; (iii) the Condensed Consolidated Statements of Comprehensive Income; (iv) the Condensed Consolidated Statements of Stockholders’ Equity; (v) the Condensed Consolidated Statements of Cash Flows; and (vi) the Condensed Notes to Consolidated Financial Statements.* |
| 104 | Cover Page Interactive Data File (Formatted as Inline XBRL and contained in Exhibit 101). |
| * | Filed herewith. |
| ** | Furnished herewith. |
| *** | Denotes management contract or compensatory plan or arrangement. |
| †† | Certain portions of the exhibit have been omitted pursuant to Rule 601(b)(10) of Regulation S-K. The omitted information (i) is not material and (ii) is the type that the Registrant treats as private or confidential. |
| ## | Schedules and exhibits have been omitted pursuant to Item 601(a)(5) of Regulation S-K. The Company hereby undertakes to supplementally furnish copies of any omitted schedules and exhibits to the Securities and Exchange Commission upon request. |
| (1) | Incorporated by reference to Exhibit 3.1 to the registrant’s Current Report on Form 8-K, filed on March 14, 2025. |
| (2) | Incorporated by reference to Exhibit 10.1 to the registrant’s Current Report on Form 8-K, filed on January 21, 2025. |
| (3) | Incorporated by reference to Exhibit 10.2 to the registrant’s Current Report on Form 8-K, filed on January 21, 2025. |
| (4) | Incorporated by reference to Exhibit 10.3 to the registrant’s Current Report on Form 8-K, filed on January 21, 2025. |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.